MetaADEDB 2.0 @ LMMD
Eflornithine
(VLCYCQAOQCDTCN-UHFFFAOYSA-N)
Structure
SMILES
NCCCC(C(=O)O)(C(F)F)N
Type(s)
Approved; Withdrawn
ATC code(s)
D11AX16; P01CX03
Molecular Formula:
C6H12F2N2O2
Molecular Weight:
182.168
Log P:
1.1731
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
3
TPSA:
89.34
CAS Number(s):
67037-37-0; 70050-56-5; 70052-12-9
Synonym(s)
1.
Eflornithine
2.
Difluoromethylornithine
3.
alpha-Difluoromethylornithine
4.
DL-alpha-Difluoromethylornithine
5.
Eflornithine Hydrochloride
6.
Eflornithine Monohydrochloride, Monohydrate
7.
MDL-71,782 A
8.
Ornidyl
9.
RMI 71782
10.
Vaniqa
11.
alpha-Difluoromethyl Ornithine
12.
DL alpha Difluoromethylornithine
13.
MDL 71,782 A
14.
MDL71,782 A
15.
Ornithine, alpha-Difluoromethyl
16.
alpha Difluoromethyl Ornithine
17.
alpha Difluoromethylornithine
External Link(s)
MeSHD000518
PubChem Compound3009
BindingDB50028197
ChEBI41948
CHEMBLCHEMBL830
DrugBankDB06243
DrugCentral990
IUPHAR/BPS Guide to PHARMACOLOGY5176
KEGGcpd:C07997
dr:D07883
Therapeutic Target DatabaseD0X7JR
D0Y4DA
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 77
Canada Vigilance: 2		Canada Vigilance
US FAERS
2Product quality issueFAERS: 35US FAERS
3AlopeciaFAERS: 13US FAERS
4AcneFAERS: 11US FAERS
5Burning sensationFAERS: 8US FAERS
6Drug dose omissionFAERS: 8US FAERS
7ErythemaFAERS: 8US FAERS
8Product availability issueFAERS: 7US FAERS
9Skin irritationFAERS: 5US FAERS
10PruritusFAERS: 4US FAERS
11HeadacheFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
12Inappropriate schedule of drug administrationFAERS: 3US FAERS
13Application site erythemaFAERS: 2US FAERS
14Application site painFAERS: 2US FAERS
15Application site rashFAERS: 2US FAERS
16Incorrect dose administeredFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
17Intentional product misuseFAERS: 2US FAERS
18Pain of skinFAERS: 2US FAERS
19Product physical consistency issueFAERS: 2US FAERS
20Application site drynessFAERS: 1US FAERS
21Application site irritationFAERS: 1US FAERS
22Application site pruritusFAERS: 1US FAERS
23Application site pustulesFAERS: 1US FAERS
24Application site ulcerFAERS: 1US FAERS
25CheilitisFAERS: 1US FAERS
26DeliriumFAERS: 1US FAERS
27DizzinessFAERS: 1US FAERS
28Drug administered at inappropriate siteFAERS: 1US FAERS
29Drug effect incompleteFAERS: 1US FAERS
30Drug exposure during pregnancyFAERS: 1US FAERS
31Drug prescribing errorFAERS: 1US FAERS
32Dry skinFAERS: 1US FAERS
33DysgeusiaFAERS: 1US FAERS
34EczemaFAERS: 1US FAERS
35Eye painFAERS: 1US FAERS
36General physical health deteriorationFAERS: 1US FAERS
37HypersensitivityFAERS: 1US FAERS
38HypertrichosisFAERS: 1US FAERS
39HypotrichosisFAERS: 1US FAERS
40Incorrect product storageFAERS: 1US FAERS
41Infusion site cellulitisFAERS: 1US FAERS
42MalaiseFAERS: 1US FAERS
43Medication residue presentFAERS: 1US FAERS
44NauseaFAERS: 1US FAERS
45PainFAERS: 1US FAERS
46Pharmaceutical product complaintFAERS: 1US FAERS
47PregnancyFAERS: 1US FAERS
48Rectal dischargeFAERS: 1US FAERS
49Skin WrinklingFAERS: 1US FAERS
50Skin tightnessFAERS: 1US FAERS
51SwellingFAERS: 1US FAERS
52Therapeutic response delayedFAERS: 1US FAERS
53ThrombocytopeniaFAERS: 1US FAERS
54Vaginal DischargeFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.